Aflac Incorporated Announces 16.0% Increase in the First Quarter 2025 DividendIn a heartwarming turn of events, the 39 search and rescue dogs in Yunnan, China, who didn't pass the official examination have sparked a wave of compassion among animal lovers. These loyal and courageous canines are now seeking new homes through adoption, and the response has been overwhelming, with nearly 700 people already signing up to provide them with love and care.
Huawei announced the successful completion of the first nationwide deployment of 5G EasyMacro high-precision positioning in underground subway tunnels in collaboration with China Mobile. This milestone achievement marks a significant leap forward in the commercial deployment of advanced 5G technologies in underground environments.In her pursuit of self-redemption, our protagonist embarks on a journey of self-discovery and healing. She spends time delving into the depths of her memories, revisiting the moments of joy and sorrow that have shaped her identity. Through introspection and reflection, she begins to unravel the tangled threads of her past and confront the ghosts of her childhood regrets.
In the world of football, discussions about the best players and teams are never-ending. Recently, there has been much debate surrounding the FIFPRO Team of the Year selection, with particular focus on whether replacing Kylian Mbappe with Mohamed Salah as the right winger would be a more sensible choice. Renowned football analyst Zhang Jun weighed in on the matter, offering his insights and analysis on this intriguing topic.
Tax reforms will make it difficult for states to pay minimum wage — Zamfara GovThe children, in turn, were thrilled to have the opportunity to meet and interact with a world-class athlete like Sun Yingsha. They eagerly listened to her advice, asked questions about her training routine, and even challenged her to a friendly match, showing their enthusiasm for the sport and their admiration for the talented player.
Furthermore, the supportive policies implemented by the Chinese government have also played a crucial role in boosting investor confidence. The government's commitment to economic stability and growth, as well as its efforts to stimulate domestic consumption and drive innovation, have reassured market participants and provided a solid foundation for the ongoing rally in A-shares.INGLEWOOD, Calif. -- LA Clippers star Kawhi Leonard , sidelined all season because of inflammation in his right knee, returned to practice Tuesday, coach Ty Lue said. Leonard could return to game action within the next two weeks, barring any setbacks, sources told ESPN. It was the first time Leonard, 33, had practiced with the team since last season. Leonard's knee also caused him to bow out of the Paris Olympics in the summer after originally being selected to play for Team USA. "He did offensive script, defensive work, and just no contact," Lue said. "But he did it pretty much everything else." Leonard could be seen leaning against a basketball stanchion after practice while James Harden and Kris Dunn got in extra shooting, but he did not speak to reporters. Editor's Picks NBA Power Rankings: Bucks bounce back, Rockets rise in the West 6d NBA Insiders Lue said Leonard looked good and added that his presence gave the team a lift. The Clippers have lost three out of their past five games and on Tuesday announced that Derrick Jones Jr . has a right hamstring strain and will be reevaluated in two weeks. "Really good sign, just seeing him out there moving, moving well," Lue said. "I think the biggest thing for him is just the confidence in it. Just having the confidence to keep doing it, not to feel the pain, and just continue to keep getting through it. "So, it was good to see him on the floor and it gave us a little juice today just for our guys seeing him on the floor, it really picked up our energy." Without Leonard, the Clippers have been a surprise success story so far, starting the season 14-11 -- sixth place in the Western Conference. They have the No. 6 defensive rating in the league, allowing 108.5 points per 100 possessions. Norman Powell has also been an early surprise after increasing his scoring average from 13.9 points last season to 23.6 points this season in a starting role, generating early Most Improved Player consideration. "I give our guys credit, our players, no matter who's been here, when guys have been out, we always feel like we have a chance to win and so just go on the floor every single night," Lue said. "Just finding ways to win. It's not going to be the same every night. It could be different every single night, but just trying to find ways to win, trying to find combinations to win. I give our guys credit, they've done that." Lue said the team would continue to be patient with the process as Leonard inches closer to a return. "He's got to do a lot more things to really get back on the floor," Lue said. "We just want to make sure he's 100%. We don't want to get him out there, 70%, 75%. Like, let's just take our time, make sure we get it right. ... We're not going to let him skip steps, and so we want to do right by Kawhi." Lue credited Leonard's mentality with injuries taking their toll on his body. He sat out the entire 2021-22 season because of a torn ACL in his right knee and has missed 204 of a possible 460 games since joining the Clippers in 2019. "I'm just happy he's doing it again, he's getting close and he's really in a good space mentally," Lue said. "So he's just got to stay with it, stay with the program. Can't get frustrated trying to rush back." And while the Clippers will gladly welcome the two-time Finals MVP version of Leonard they signed as a free agent in 2018, there's no expectation for him to be that player as soon as he's back in the lineup. "At some point, not right away," Lue said. "But at some point, we need him to be Kawhi Leonard. And I think he can do that. And just seeing the year he had last year -- 68 games and how he played at a high level. He was really, really playing at a high level. So we just got to get him back to that."
Prue Leith says Gregg Wallace shouldn't be sacked and slams 'weak' TV bosses
Aflac Incorporated Announces 16.0% Increase in the First Quarter 2025 Dividend
Title: A Baby's Rollercoaster of Emotions in Just a Few Seconds of Getting a Shot
SINGAPORE: A new ambulance traffic priority system was activated 76 times during life-threatening emergencies for three routes near Ng Teng Fong General Hospital (NTFGH) over a three-month period. It reduced the time taken to send the patients to the hospital by an average of 1 minute and 40 seconds, the Singapore Civil Defence Force (SCDF) said in a press release on Saturday (Nov 23). This was according to data collected from Jul 15 to Oct 15 during the first phase of implementation. The system, which was co-developed by the SCDF, Land Transport Authority (LTA) and Home Team Science and Technology Agency, uses an in-vehicle device to "activate priority passage" for ambulances at traffic junctions near hospitals. Phase one of the system's implementation involved two ambulances operating from Jurong Fire Station and one from Bukit Batok Fire Station. “The implementation of phase 1 of the traffic priority system has shown encouraging results, where there was an observable reduction in the time needed to convey patients with life-threatening emergencies to the hospital," said SCDF chief medical officer Hong Dehan. "Every second saved can be the difference between life and death, particularly for cases of cardiac arrest, trauma or stroke. This capability will allow us to save valuable time by enabling faster conveyance of patients to the hospital, potentially improving patient outcomes and their chances of survival.” WHAT IS THE SYSTEM? The traffic priority system, which was announced during the SCDF’s Workplan Seminar earlier this year, is for emergency ambulances that are within the "final mile" when taking a patient to a hospital. Designated traffic junctions near hospitals are installed with roadside equipment - used to send and receive messages from nearby vehicles - that is linked to the traffic light controller. When an ambulance is within 200m of these junctions, its on-board device will be activated. The equipment will then trigger the traffic lights in favour of the ambulance. When the traffic priority system is activated, the affected traffic light junctions will still proceed as usual with the normal sequence of lights, but with specific phases becoming shorter. It will be used only in life-threatening cases, said SCDF. During the first phase, roadside equipment was installed in the vicinity of Ng Teng Fong General Hospital, which lies within the "response boundary" of the two fire stations. HOW IT HAS HELPED PATIENTS Paramedics said the traffic priority system is important in life-threatening emergencies. For paramedic Sharon Tan, the system proved its worth during a case in September, when a woman in her 50s suffered a cardiac arrest. The unconscious woman was sent from a Jurong West void deck to the hospital in about six minutes - quicker than the usual time for that route. "I find that the (traffic priority system) is quite beneficial in terms of pre-hospital care," explained SGT3 Tan. "It allows us to reach the hospital as fast as possible. Every second matters for these kinds of cases, especially when it involves an organ like the heart." Upon arriving at the hospital, the unconscious woman regained her pulse. Prior to phase 1, trials were conducted at traffic junctions near NTFGH and Khoo Teck Puat Hospital, which indicated time savings of "about 30 to 100 seconds per conveyance". In the second phase, on-board devices will be installed for all other SCDF ambulances. Coverage will also be extended to three more hospitals - Khoo Teck Puat Hospital, Changi General Hospital and National University Hospital. This is scheduled for completion by the second quarter of 2025. The final phase will include all remaining public hospitals by the fourth quarter of next year. By 2026, the traffic priority system is expected to be fully rolled out. This will involve outfitting all SCDF emergency ambulances and 47 traffic junctions serving all nine public hospitals.THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE Amgen
Trump taps forceful ally of hard-line immigration policies to head Customs and Border ProtectionThe response from the community has been nothing short of amazing, with hundreds of compassionate individuals stepping forward to offer a forever home to these deserving dogs. The diversity of candidates ranging from families, singles, seniors, and even organizations reflects the universal appeal and admiration for these remarkable animals and their selfless nature.Ducks hope to snap 3-game skid in Ottawa or Toronto
